In Japan, the prevalence of gBRCA1/2 mutations in advanced ovarian cancer (FIGO stage III or IV) is 24.1 % (BRCA1: 16.3 %, BRCA2: 7.7 %), and overall, the proportion of gBRCA1/2 mutations in ovarian cancer (FIGO stage I–IV) is 14.7 % (BRCA1: 9.9 %, BRCA2: 4.7 %), aligning with prevalence rates in Europe and the United States (Enomoto et al., 2019). The gene discussed is BRCA2; the disease is ovarian carcinoma.